Vyne Therapeutics Inc
NASDAQ:VYNE

Watchlist Manager
Vyne Therapeutics Inc Logo
Vyne Therapeutics Inc
NASDAQ:VYNE
Watchlist
Price: 0.57 USD 0.16% Market Closed
Market Cap: 19m USD

Operating Margin
Vyne Therapeutics Inc

-7 162.4%
Current
-6 978%
Average
5.9%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-7 162.4%
=
Operating Profit
-37.5m
/
Revenue
524k

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Vyne Therapeutics Inc
NASDAQ:VYNE
18.1m USD
-7 162%
US
Eli Lilly and Co
NYSE:LLY
1T USD
44%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
491.8B USD
27%
CH
Roche Holding AG
SIX:ROG
271.4B CHF
34%
UK
AstraZeneca PLC
LSE:AZN
220.4B GBP
24%
US
Merck & Co Inc
NYSE:MRK
274.9B USD
38%
CH
Novartis AG
SIX:NOVN
218.8B CHF
33%
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
42%
IE
Endo International PLC
LSE:0Y5F
213.9B USD
11%
US
Pfizer Inc
NYSE:PFE
144.9B USD
29%
No Stocks Found

Vyne Therapeutics Inc
Glance View

Market Cap
18.1m USD
Industry
Pharmaceuticals

VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. The company is headquartered in Bridgewater, New Jersey and currently employs 28 full-time employees. The company went IPO on 2018-01-25. The firm is engaged in developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions and rare skin diseases with high unmet medical need. The Company’s proprietary pipeline FMX114, which is a potential treatment of mild-to-moderate atopic dermatitis in patients 12 years of age and older, and access to a library of bromodomain and extra-terminal (BET) domain inhibitors in both topical and oral forms for the potential treatment of major immuno-inflammatory conditions and rare skin diseases.

VYNE Intrinsic Value
HIDDEN
Show
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-7 162.4%
=
Operating Profit
-37.5m
/
Revenue
524k
What is the Operating Margin of Vyne Therapeutics Inc?

Based on Vyne Therapeutics Inc's most recent financial statements, the company has Operating Margin of -7 162.4%.

Back to Top